Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Debt Issuance
confidence 92%
filed 2026-07-28
Item 1.01
Apple Hospitality REIT entered into a Fourth Amended and Restated Credit Agreement on July 23, 2026, materially restructuring its debt obligations by increasing the revolving credit facility from $650 million to $700 million, extending term loan maturities from 2027–2028 to 2031–2032, and improving pricing terms. The refinancing also increased the Main Credit Facility from $1.2 billion to $1.3 billion (with accordion to $1.75 billion) and increased the term loan from $130 million to $160 million with extended maturity to July 24, 2033, enhancing the company's liquidity and balance sheet flexibility.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-28
Item 2.02
FB Bancorp issued a press release on July 28, 2026 reporting financial results for the quarter and six months ended June 30, 2026, disclosing net income from continuing operations, discontinued operations, and detailed financial metrics. This is a standard quarterly earnings release attached as Exhibit 99.1 and disclosed under Item 2.02 (Results of Operations and Financial Condition), which is the typical vehicle for earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-28
Item 2.02
This is a clear earnings release disclosing consolidated financial results for the three and six months ended June 30, 2026. The press release (Exhibit 99.1) reports GAAP net earnings of $0.05 per share (Q2 2026 vs. $0.01 in Q2 2025), FFO As Adjusted of $0.31 per share (vs. $0.28 in Q2 2025), same-property NOI growth of 8.7%, and raised full-year 2026 guidance. This is a standard quarterly earnings announcement filed under Item 2.02 and is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-28
Item 2.02
Landstar System Inc. released its second quarter 2026 financial results, reporting revenue of $1.432 billion (18% increase year-over-year), EPS of $1.44 (20% increase year-over-year), and gross profit of $132 million (21% increase year-over-year). The disclosure includes detailed financial statements, operational metrics, and a slide presentation accompanying a conference call scheduled for July 28, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-28
Item 2.03
AT&T closed its acquisition of wireless spectrum licenses from EchoStar for approximately $23 billion, adding significant spectrum assets (approximately 50 MHz across low-band and mid-band frequencies) nationwide. The company financed the transaction by drawing $14.5 billion ($11.5 billion on a two-year term loan facility plus $3.0 billion on a 364-day term loan facility) from its $17.5 billion Delayed Draw Term Loan Credit Agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
North Haven Private Income Fund A LLC completed an unregistered sale of approximately 19,523 Class I units for $0.4 million, relying on Section 4(a)(2) and Regulation D exemptions with accredited investor representations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-07-28
Item 7.01
The Fund declared a distribution to unitholders of $0.1411 per unit payable on August 5, 2026, representing a material capital return to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-28
Item 2.02
This is a clear earnings release disclosing Slide Insurance Holdings' financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports key metrics including gross premiums written of $508.0 million (16.7% YoY growth), net income of $134.9 million (92.4% YoY growth), diluted EPS of $1.06, and an improved combined ratio of 57.6%. The filing includes condensed consolidated statements of operations and balance sheets, making this a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
West Bay BDC LLC is conducting an unregistered sale of approximately 1.6 million common units for $27.8 million to existing investors pursuant to subscription agreements and capital drawdown notices. The sale is exempt under Section 4(a)(2) and Regulation D, with purchasers required to be accredited investors or non-U.S. persons. This is a classic dilutive issuance of equity securities to raise capital, material to investors assessing the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-28
Item 7.01
NeuroPace received FDA notification that its Premarket Approval Supplement (PMA-S) for indication expansion into idiopathic generalized epilepsy is "not approvable in its current form" and requires additional clinical evidence. This is a material regulatory setback for a key product expansion that directly impacts the company's growth strategy and market access. While not a formal denial, the non-approvability determination is a significant operational and regulatory milestone that would affect investor assessment of the company's near-term commercial prospects and pipeline execution.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-28
Item 7.01
The filing discloses entry into a Fifth Amended and Restated Revolving Credit and Term Loan Agreement that increases the facility from $940 million to $1.15 billion, including a new $400 million senior unsecured term loan maturing in August 2031. This represents creation of a new direct financial obligation and material refinancing activity. While the amendment also extends existing debt maturities and improves credit spreads, the principal disclosed action is the issuance of the new $400 million term loan, which is a debt_issuance event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
North Haven Private Income Fund LLC completed an unregistered sale of approximately 122,704 Class S units for $2.20 million, relying on Section 4(a)(2) and Regulation D exemptions with accredited investor representations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-28
Item 7.01
North Haven Private Income Fund LLC declared a distribution of $0.1206 per unit payable on or around August 5, 2026, as disclosed on July 24, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-28
Item 2.02
Trustmark Corporation issued a press release on July 28, 2026, announcing its second quarter 2026 financial results, including net income of $63.5 million, diluted EPS of $1.08, ROATE of 14.08%, and ROAA of 1.33%. The disclosure includes comprehensive financial metrics, balance sheet management details, credit quality analysis, revenue generation, and noninterest expense information—all hallmarks of a quarterly earnings release. This is a material disclosure affecting investor assessment of the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-07-28
Item 7.01
The disclosure centers on a regular distribution to unitholders of $0.1383 per unit declared on July 24, 2026, payable August 5, 2026. While the filing also includes portfolio composition and NAV information under Regulation FD, the primary material event disclosed is the distribution declaration. For a closed-end fund or BDC-like vehicle, distributions to unitholders are material capital events affecting investor returns and are typically classified as dividend_distribution.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-07-28
Item 5.07
Tempest Therapeutics held a special stockholder meeting on July 27, 2026 to vote on a Certificate of Amendment proposal to modify voting requirements and permit written consent. The proposal failed to achieve the required 75% supermajority vote, and the meeting was adjourned to August 17, 2026 to allow additional voting time.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 85%
filed 2026-07-28
Item 8.01
The filing discloses multiple loan defaults and accelerations affecting NYRT's indirect investment in One Worldwide Plaza: a $940M first mortgage in monetary default as of December 2025, a $190M senior mezzanine loan in default since September 2024 with acceleration triggered in October 2025, and a $70M junior mezzanine loan in default. These defaults constitute covenant breaches that have triggered acceleration of debt obligations and foreclosure proceedings, representing a material triggering event affecting the registrant's financial obligations and the value of its core asset.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The Board of Directors elected Evan Yu to the Board effective August 1, 2026, as an independent director. Yu is a seasoned global semiconductor executive with prior experience at Diodes (2008–2023) and other major semiconductor firms, bringing deep expertise in power products and international operations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-28
Item 1.01
Seritage Growth Properties entered into two new loan agreements with b1Bank on July 24, 2026: a $15.0 million term loan facility and a $25.0 million revolving loan facility, with $15.0 million drawn at closing. The company used proceeds to refinance and repay an existing $50.0 million loan from Berkshire Hathaway that was due July 31, 2026, representing a material refinancing of the company's debt structure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-28
Item 8.01
The Board of Trustees declared a cash dividend of $0.4375 per share on the Company's 7.00% Series A Cumulative Redeemable Preferred Shares, payable on October 15, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-28
Item 8.01
IonQ announced on July 28, 2026, that it received final regulatory approval to complete its acquisition of SkyWater Technology, a material M&A transaction previously disclosed on January 25, 2026. The filing discloses the anticipated closing date of July 31, 2026, and describes the two-step merger structure whereby SkyWater will become a wholly owned subsidiary of IonQ. This is a material acquisition that would significantly affect investor assessment of IonQ's business, strategy, and financial position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-28
Item 2.02
Ashland Inc. announced preliminary third quarter 2026 financial results on July 28, 2026, disclosing sales of $497 million (up 7% year-over-year), income from continuing operations of $41 million ($0.89 per diluted share), and Adjusted EBITDA of $109 million, while reaffirming full-year fiscal 2026 sales guidance of $1,835–$1,870 million and Adjusted EBITDA guidance of $385–$400 million.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-28
Item 5.02
Nick Daffan is departing his role as Executive Vice President and Chief Information Officer effective August 3, 2026, though he will transition to a Strategic Advisor role through year-end. The principal disclosed action is the departure from his executive officer position after more than 20 years with the company. While a successor (Jeff Negrete as interim CIO) is mentioned, the core event is Daffan's departure from his executive role, making this an exec_departure rather than an appointment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-28
Item 5.02
The disclosure centers on the Compensation and Human Capital Committee's approval of a one-time restricted stock unit award of $500,000 to E.J. Wunsch, President of International, granted under the 2020 Omnibus Award Plan with two-year vesting. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category. While the filing mentions Robert D. Wright's appointment as CEO, the substantive Item 5.02(e) disclosure is the equity grant to Wunsch.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-28
Item 8.01
SCE Recovery Funding issued $1,953,948,000 of Senior Secured Recovery Bonds, Series 2026-A on July 28, 2026, pursuant to California's Wildfire Financing Law. This represents a material creation of a direct financial obligation secured by recovery property (fixed recovery charges authorized by the California Public Utilities Commission). The issuance is supported by multiple ancillary agreements (Indenture, Servicing Agreement, Purchase and Sale Agreement, Administration Agreement, and Intercreditor Agreement) and a legal opinion addressing constitutional protections of the bond structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-07-28
Item 5.02
Ashland appointed two new independent directors, Peter Thomas (former CEO of Ferro Corporation) and Allen Spizzo (former CFO of Hercules Incorporated), effective July 27, 2026, as part of a Cooperation Agreement with activist stockholder Ancora Holdings Group, LLC. The appointments include roles on a newly formed Capital Allocation Advisory Committee and reflect material board refreshment driven by shareholder engagement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-28
Item 2.02
Blue Ridge Bankshares issued a press release on July 28, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net loss of $0.2 million, net interest income of $16.5 million, and other key financial metrics. This is a standard quarterly earnings release furnished under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-28
Item 8.01
SkyWater disclosed receipt of final regulatory approval to consummate its acquisition by IonQ, with closing anticipated for July 31, 2026. The filing describes a two-step merger structure whereby SkyWater will become a wholly owned subsidiary of IonQ. This is a material change of control transaction that would significantly affect a reasonable investor's assessment of SkyWater's future as an independent company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-28
Item 7.01
Verra Mobility announced a framework agreement with Avis Budget Group on a new seven-year tolling and violations services contract. The press release explicitly states that "the terms of the new agreement are expected to be materially less favorable to the Company when compared to the prior agreement," signaling a material renegotiation of a significant customer relationship. This is a material operational/commercial event affecting the company's revenue and customer relationships, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-28
Item 1.01
American Airlines announced the pricing of enhanced equipment trust certificates totaling approximately $1.33 billion in aggregate face amount. This constitutes the creation of a new direct financial obligation through debt issuance, which is a material capital-raising event for the registrant. The Item 1.01 classification and the specific disclosure of pricing for Class A and Class B certificates confirm this is a debt issuance transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-28
Item 1.01
The Formation Agreement establishes a new Hong Kong-incorporated entity ("Maison AI Limited") in which Maison Solutions' subsidiary AZLL will hold ~90% ownership and contribute software valued at US$2,000,000, while external parties contribute US$220,000 in cash. This constitutes entry into a material definitive agreement for formation of a joint venture or controlled subsidiary with significant asset contribution and equity structure, fitting the M&A activity category under Item 1.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-28
T1 Energy acquired intellectual property and related assets from Evervolt Green Energy for $135 million total consideration ($2 million option premium plus $133 million purchase price). The filing discloses entry into a material definitive IP Purchase Agreement (Item 1.01), completion of the acquisition (Item 2.02), and termination of existing license agreements (Item 1.02). The transaction involves acquisition of foundational solar patents and TOPCon technology previously licensed, representing a material acquisition of assets that eliminates future royalty obligations and advances the company's strategic position as a vertically integrated solar manufacturer.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-07-28
Item 2.02
T1 Energy Inc. disclosed preliminary financial and operating results for Q2 2026, including total net sales of $245–$255 million, net loss from continuing operations of $34.0–$37.0 million, adjusted EBITDA of ($14.5)–($11.5) million, and a cash position of $156.4 million as of June 30, 2026, along with forward-looking guidance and non-GAAP reconciliations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-28
EX-99.1
Kazia announced the filing of a provisional patent application for a novel therapeutic strategy to prevent metastatic recurrence in triple-negative breast cancer, supported by preclinical data showing 95% reduction in residual disease and 40% reduction in lung metastatic burden. The company also announced plans to broaden clinical development of paxalisib into earlier-stage TNBC. This is a material operational/strategic milestone—a significant expansion of the drug candidate's development pathway and intellectual property protection—but does not fit the specific event categories of earnings release, executive changes, M&A, impairment, or other named types. The preclinical findings and patent filing represent a meaningful advancement in the company's pipeline strategy that would affect a reasonable investor's assessment of paxalisib's potential market opportunity.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-28
Item 2.02
SunPower issued a press release on July 28, 2026 announcing preliminary unaudited financial results for Q2 2026, including revenue of $56.0 million (down $16.8 million from Q1), operating losses, and updated Q3 2026 guidance projecting $75+ million revenue and 90% reduction in operating loss.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
EX-99.1
Enlivex announced a $400 million private placement of ordinary shares at $5.00–$6.00 per share to a single institutional investor, with an additional $400 million call option exercisable over 36 months on identical terms. This is a material unregistered equity issuance (private placement) that will significantly dilute existing shareholders and raise substantial capital. The filing explicitly notes that closing is subject to shareholder approval under Nasdaq Listing Rule 5635, confirming the dilutive nature and materiality of the transaction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-28
Item 7.01
Turn Therapeutics disclosed an updated investor presentation on July 28, 2026, detailing clinical trial progress for GX-03 (Phase 2 interim data for atopic dermatitis showing encouraging efficacy signals, upcoming Phase 3 initiation timelines) and pipeline expansion into onychomycosis and hidradenitis suppurativa. This is a material operational/strategic disclosure of clinical development milestones and product pipeline advancement, but does not fit the specific categories of earnings release, M&A, executive changes, or other defined event types. The disclosure of Phase 2 interim efficacy data and Phase 3 readiness for a lead therapeutic candidate would affect a reasonable investor's assessment of the company's clinical progress and commercial prospects.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 7.01
The filing discloses the appointment of Bipin Dalmia, PhD, MBA as Chief Business Officer of Relmada Therapeutics, effective July 28, 2026. The press release emphasizes his nearly three decades of biopharmaceutical leadership, his expertise in NMIBC and intravesical therapies, and his direct reporting relationship to the CEO. This is a material executive appointment to a senior officer role at a clinical-stage biotechnology company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-28
EX-99.1
This is a subscription agreement for an unregistered sale of ordinary shares by Star Fashion Culture Holdings Ltd to Xingji Zhangpingting Limited pursuant to Regulation S, at $1.30 per share. The agreement explicitly states the shares are "restricted securities" and the offering is structured as an offshore transaction to non-U.S. persons to avoid Securities Act registration. This is a classic private placement / dilutive issuance of equity securities outside the registered public market, material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-28
Item 7.01
The filing discloses the Board of Directors' declaration of a special cash dividend of US$0.5 million (approximately US$0.04 per share) with a record date of August 17, 2026 and expected payment on or about September 30, 2026. This is a clear dividend distribution event that would materially affect shareholder value and capital allocation decisions.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-07-28
Item 1.01
BiomX amended a $1.25M promissory note from its April 2026 ZorroNet acquisition, extending the maturity date from July 10 to November 1, 2026, restructuring principal payments into monthly installments, and issuing 800,000 restricted shares as consideration for the extension and waiver of default.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-28
EX-99.1
This exhibit discloses the results of Karooooo Limited's Annual General Meeting held on July 28, 2026, including detailed voting outcomes on six resolutions covering routine business (director re-appointment, financial statement adoption, non-executive director remuneration, auditor re-appointment) and special business (share purchase authorization, share issuance authorization). The tabular presentation of votes cast for, against, and abstained on each resolution is the hallmark of shareholder_vote_results disclosure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
EX-99.1
The exhibit announces the closing of a registered direct offering of 1,281,646 ADSs (representing 384,493,800 ordinary shares) at US$3.16 per ADS, raising approximately US$4.1 million in gross proceeds. The offering also includes concurrent private placement of unregistered warrants to purchase additional ADSs, plus a separate Australian private placement and Share Purchase Plan. This is a material dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital through registered and unregistered securities offerings.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-28
EX-99.3
This is a press release announcing Cheer Holding's first half 2026 financial results for the six months ended June 30, 2026. The document discloses key financial metrics including revenues ($60.5M, down 14.7% YoY), operating income (up 26.1% to $10.5M), net income (up 4.0% to $8.1M), gross margin improvement to 76.7%, and cash position of $213.8M. As a half-year results announcement from a foreign private issuer, this is a material earnings disclosure that would affect investor assessment of the company's financial performance and operational efficiency.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-28
EX-99.1
CollPlant is holding an extraordinary general meeting scheduled for August 18, 2026, to seek shareholder approval for a reverse stock split (at a ratio between 1-for-8 and 1-for-12) and elimination of par value. The reverse split is being undertaken to address Nasdaq minimum bid price non-compliance and associated delisting risk.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-28
The Company entered into a Share Purchase Agreement on July 27, 2026, to sell all issued and outstanding shares of Australian Oilseeds Investments Pty Ltd and its subsidiaries, which collectively carry on the Company's oilseed crushing and edible oils business. This constitutes a material disposition of a significant operating business segment, meeting the definition of ma_activity under Item 1.02 (Unregistered Sales of Equity Securities) or Item 2.01 (Completion of Acquisition or Disposition of Assets).
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-28
EX-99.1
Ellomay's Luxembourg subsidiary signed an agreement to acquire 100% of a project company holding a 51.75 MW / 207 MWh battery energy storage system in northern Italy. This is a material acquisition of a ready-to-build energy asset, representing Ellomay's entry into the Italian battery storage market. The transaction is subject to conditions precedent with a deadline of end-2027, consistent with Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition) disclosure requirements.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-28
EX-99.3
This is a press release dated July 28, 2026, announcing FST Corp.'s unaudited financial results for the second quarter ended June 30, 2026. The exhibit discloses Q2 2026 revenue of $12.6 million (9.7% YoY increase), a net loss of $1.0 million (improved from $3.0 million loss in Q2 2025), and six-month net income of $831,189. The release includes consolidated balance sheets, statements of operations, and cash flow statements, along with management commentary on strategic initiatives. This is a discrete earnings announcement, not a periodic financial report filing, and the financial improvements and operational metrics disclosed would materially affect a reasonable investor's assessment of the company's performance and trajectory.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-28
The Board approved adoption of a restricted stock award (RSA) program under the 2025 Equity Incentive Plan on July 25, 2026, reserving 1,340,000 ordinary shares (approximately 3% of outstanding shares) for grant and settlement of RSAs with three-year vesting tied to continued service. This is a compensatory arrangement for directors and officers that materially affects equity structure and would be disclosed under Item 5.02(e) equivalent in a domestic 8-K.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-07-28
Mr. Ho Wai Alan Chung resigned as an independent director and chair of the nominating committee, effective July 31, 2026. The disclosure explicitly states the resignation was accepted by the Board and provides details on his committee roles and the reason for departure (pursuing other professional business, not due to disagreement). This is a clear executive departure requiring disclosure under Item 5.02 equivalent for foreign private issuers, and is material as it affects board composition and committee leadership.
View raw filing on EDGAR →